The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Medpace Holdings Inc. (NASDAQ: MEDP) common stock between April 22, 2025 and February 9, 2026, inclusive (the ...
Medicare's Hemp Program Continues Despite Federal Restrictions Taking Effect in Less Than Six MonthsCourt Declines to Address Safety, Legality, or Congressional Intent, Allowing CMS Hemp Program to ...
ETX-19477 demonstrated robust efficacy, with a 57% objective response rate in BRCA-mutated platinum-resistant ovarian cancer and earlier-line HR+/HER2- breast cancer (n=7) ---- Favorable safety ...
LONDON, UK / ACCESS Newswire / May 23, 2026 / MYTRT, a UK-based digital healthcare platform, has announced the launch of a service for people seeking information, testing and clinical assessment ...
Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...
Study conducted with Severance Hospital shows whole-genome sequencing-based HRD phenotyping was associated with longer progression-free survival in patients receiving PARP inhibitor maintenance ...
Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, ...
Proposed dual listing expected to broaden access to US investors as buloxibutid advances toward its Phase 2b readout in IPF, with no concurrent financing or share offering planned STOCKHOLM, SWEDEN ...
SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three ...
Twenty-three abstracts will highlight the versatility and strength of Genmab’s portfolio and pipeline, including data from the comprehensive epcoritamab development program, including 4 oral ...
AUSTIN, Texas--(BUSINESS WIRE)--#AnimalHealth--VMD Sciences (VMDS) recently announced expanded efforts to support large animal veterinarians facing increasing therapeutic constraints due to an ongoing ...
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with AgiosAvanzanite is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results